REDS: Sales stable, losses widened, cash up; strong Q4 expected with new product launch

About this update from Redsense Medical Ab

Q3 2024 saw stable sales and improved gross margin, but operating losses widened amid management changes. Cash position strengthened, and a strong Q4 is anticipated with new product launches and continued US market focus.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Redsense Medical Ab